Table 3.
Bioactivities | ||||||||
---|---|---|---|---|---|---|---|---|
Antioxidant Activity EC50 Values 1 (µg/mL) | Antimicrobial Values (mg/mL) | |||||||
OxHLIA | Mesquite | Streptomycin | Ampicillin | |||||
Δt = 60 min | 100 ± 5 | Gram negative bacteria | MIC | MBC | MIC | MBC | MIC | MBC |
Δt = 120 min | 233 ± 5 | Escherichia coli | 0.20 | 0.30 | 0.20 | 0.30 | 0.40 | 0.50 |
TBARS | 470 ± 6 | Enterobacter cloacae | 0.30 | 0.60 | 0.20 | 0.30 | 0.25 | 0.50 |
Cytotoxicity GI50 Values2 (μg/mL) | Salmonella Typhimurium | 0.20 | 0.30 | 0.20 | 0.30 | 0.75 | 1.20 | |
MCF-7 (breast carcinoma) | >400 | Gram positive bacteria | ||||||
NCI-H460 (non-small cell lung carcinoma) | 242 ± 4 | Staphylococcus aureus | 0.60 | 0.80 | 0.04 | 0.10 | 0.25 | 0.45 |
HeLa (cervical carcinoma) | >400 | Listeria monocytogenes | 0.40 | 0.60 | 0.20 | 0.30 | 0.40 | 0.50 |
HepG2 (hepatocellular carcinoma) | >400 | Antifungal Values (mg/mL) | ||||||
Hepatotoxicity GI50 Values 2 (μg/mL) | Mesquite | Ketoconazole | Bifonazole | |||||
PLP2 | >400 | MIC | MFC | MIC | MFC | MIC | MFC | |
Aspergillus fumigatus | n.a | n.a | 0.25 | 0.50 | 0.15 | 0.20 | ||
Aspergillus ochraceus | 0.15 | 0.30 | 0.20 | 0.50 | 0.10 | 0.20 | ||
Aspergillus niger | n.a | n.a | 0.20 | 0.50 | 0.15 | 0.20 | ||
Penicillium ochrochloron | 0.075 | 0.15 | 2.5 | 3.5 | 0.20 | 0.25 | ||
Penicillium funiculosum | 0.15 | 0.30 | 0.20 | 0.50 | 0.20 | 0.25 | ||
P. verrucosum var. cyclopium | 0.30 | 0.80 | 0.20 | 0.30 | 0.10 | 0.20 |
1 EC50 values correspond to the sample concentration achieving 50% of the antioxidant activity or 0.5 of absorbance in reducing power assay. 2 GI50 values correspond to the sample concentration achieving 50% of growth inhibition in human tumor cell lines or liver primary culture PLP2. Trolox EC50 values: 5.8 ± 0.6 (TBARS); OxHLIA 85 ± 2 (Δt = 60 min) and 183 ± 4 (Δt = 120 min). GI50 values: 1.21 mg/mL (MCF-7); 1.03 mg/mL (NCI-H460); 0.91 mg/mL (HeLa); 1.10 mg/mL (HepG2) and 2.29 mg/mL (PLP2). n.a not activity.